

La Jolla Pharmaceutical Company (LJPC) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/LE430CC83FCEN.html>

Date: March 2021

Pages: 46

Price: US\$ 125.00 (Single User License)

ID: LE430CC83FCEN

Abstracts

La Jolla Pharmaceutical Company (LJPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

La Jolla Pharmaceutical Company (La Jolla) discovers, develops and commercializes biopharmaceutical products for life threatening diseases. The company's major product includes the US FDA approved Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. Its investigational product candidates include LJPC-0118 intended for the treatment of severe malaria and LJPC-401, a proprietary formulation of synthetic human hepcidin, an endogenous peptide hormone intended for the prevention of excessive iron accumulation in vital organs. The company sells Giapreza to hospitals in the US through a network of wholesale and specialty distributors. La Jolla is headquartered in San Diego, California, the US.

La Jolla Pharmaceutical Company Key Recent Developments

Dec 31,2020: La Jolla Pharmaceutical announces financial results for the three and twelve months ended December 31, 2020

Nov 09,2020: La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2020

Oct 29,2020: La Jolla Pharmaceutical Company announces appointment of Larry

Edwards

Sep 30,2020: La Jolla Pharmaceutical announces change of certain officers

Aug 06,2020: La Jolla Pharmaceutical announces financial results for the three and six months ended June 30, 2020 and highlights recent corporate progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

La Jolla Pharmaceutical Company - Key Facts
La Jolla Pharmaceutical Company - Key Employees
La Jolla Pharmaceutical Company - Key Employee Biographies
La Jolla Pharmaceutical Company - Major Products and Services
La Jolla Pharmaceutical Company - History
La Jolla Pharmaceutical Company - Company Statement
La Jolla Pharmaceutical Company - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
La Jolla Pharmaceutical Company - Business Description
La Jolla Pharmaceutical Company - SWOT Analysis
SWOT Analysis - Overview
La Jolla Pharmaceutical Company - Strengths
La Jolla Pharmaceutical Company - Weaknesses
La Jolla Pharmaceutical Company - Opportunities
La Jolla Pharmaceutical Company - Threats
La Jolla Pharmaceutical Company - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Type,
2015 to YTD 2021

La Jolla Pharmaceutical Company, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Dec 31, 2020: La Jolla Pharmaceutical announces financial results for the three and twelve months ended December 31, 2020

Nov 09, 2020: La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2020

Oct 29, 2020: La Jolla Pharmaceutical Company announces appointment of Larry Edwards

Sep 30, 2020: La Jolla Pharmaceutical announces change of certain officers

Aug 06, 2020: La Jolla Pharmaceutical announces financial results for the three and six months ended June 30, 2020 and highlights recent corporate progress

Jul 28, 2020: Larry Edwards appointed president and chief executive officer of La Jolla Pharmaceutical Company

Jun 02, 2020: La Jolla Pharmaceutical Company announces board changes

May 04, 2020: La Jolla Pharmaceutical Company announces financial results for the three months ended March 31, 2020

Mar 02, 2020: La Jolla Pharmaceutical Company announces financial results for the three and twelve months ended December 31, 2019

Jan 09, 2020: La Jolla Pharmaceutical Company announces preliminary GIAPREZA (Angiotensin II) net sales for the three and twelve months ended December 31, 2019

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

La Jolla Pharmaceutical Company, Key Facts
La Jolla Pharmaceutical Company, Key Employees
La Jolla Pharmaceutical Company, Key Employee Biographies
La Jolla Pharmaceutical Company, Major Products and Services
La Jolla Pharmaceutical Company, History
La Jolla Pharmaceutical Company, Subsidiaries
La Jolla Pharmaceutical Company, Key Competitors
La Jolla Pharmaceutical Company, Ratios based on current share price
La Jolla Pharmaceutical Company, Annual Ratios
La Jolla Pharmaceutical Company, Annual Ratios (Cont...1)
La Jolla Pharmaceutical Company, Interim Ratios
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
La Jolla Pharmaceutical Company, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

La Jolla Pharmaceutical Company, Performance Chart (2016 - 2020)

La Jolla Pharmaceutical Company, Ratio Charts

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: La Jolla Pharmaceutical Company (LJPC) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/LE430CC83FCEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LE430CC83FCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

